Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

被引：2
|
作者：
Pipe, Steven [1 ]
Collins, Peter [2 ]
Dhalluin, Christophe [3 ]
Kenet, Gili [4 ,5 ]
Schmitt, Christophe [3 ]
Buri, Muriel [3 ]
Jimenez-Yuste, Victor [6 ]
Peyvandi, Flora [7 ,8 ]
Young, Guy [9 ]
Oldenburg, Johannes [10 ]
Mancuso, Maria Elisa [11 ,12 ]
Kavakli, Kaan [13 ]
Kiialainen, Anna [3 ]
Chang, Tiffany [14 ]
Lehle, Michaela [3 ]
Niggli, Markus [3 ]
Fijnvandraat, Karin [15 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Cardiff Univ, Sch Med, Cardiff, Wales
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Sheba Med Ctr, Ramat Gan, Israel
[5] Tel Aviv Univ, Tel Aviv, Israel
[6] Univ Autonoma Madrid, La Paz Univ Hosp Idi Paz, Madrid, Spain
[7] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy
[8] Univ Milan, Milan, Italy
[9] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[10] Univ Bonn, Bonn, Germany
[11] IRCCS Humanitas Res Hosp, Rozzano, Italy
[12] Humanitas Univ, Rozzano, Italy
[13] Ege Univ, Fac Med, Childrens Hosp, Izmir, Turkiye
[14] Spark Therapeut Inc, San Francisco, CA USA
[15] Univ Amsterdam, Amsterdam, Netherlands
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-177963
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] CHIEF: A retrospective self-control study of children with severe hemophilia A without inhibitors comparing emicizumab to FVIII prophylaxis
    Mashiach, Daniel
    Mead, Patrice
    Carneiro, Kendall
    Malvar, Jemily
    Knight, Susan
    Young, Guy
    PEDIATRIC BLOOD & CANCER, 2024, 71 (12)
  • [42] The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
    Skinner, Mark W.
    Negrier, Claude
    Paz-Priel, Ido
    Chebon, Sammy
    Jimenez-Yuste, Victor
    Callaghan, Michael U.
    Lehle, Michaela
    Niggli, Markus
    Mahlangu, Johnny
    Shapiro, Amy
    Shima, Midori
    Campinha-Bacote, Avrita
    Levy, Gallia G.
    Oldenburg, Johannes
    von Mackensen, Sylvia
    Pipe, Steven W.
    HAEMOPHILIA, 2021, 27 (05) : 854 - 865
  • [43] Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement
    Santagostino, Elena
    Elisa Mancuso, Maria
    Novembrino, Cristina
    Solimeno, Luigi Piero
    Tripodi, Armando
    Peyvandi, Flora
    HAEMATOLOGICA, 2019, 104 (08) : E380 - E382
  • [44] RESOURCE CONSUMPTION ANALYSIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS ON PROPHYLAXIS WITH FVIII BEFORE SWITCHING TO EMICIZUMAB
    Giacomini, E.
    Leogrande, M.
    Motta, L.
    Tempre, R.
    Bendinelli, S.
    Degli Esposti, L.
    VALUE IN HEALTH, 2023, 26 (12) : S69 - S69
  • [45] ELIMINATION OF FACTOR-VIII INHIBITORS IN 7 CHILDREN WITH SEVERE HEMOPHILIA-A
    KREUZ, W
    SCHARRER, I
    HAEMOSTASIS, 1985, 15 (01) : 20 - 20
  • [46] Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe
    Mancuso, Maria Elisa
    Castaman, Giancarlo
    Pochopien, Michal
    Aballea, Samuel
    Drzewiecka, Aleksandra
    Hakimi, Zalmai
    Nazir, Jameel
    Fatoye, Francis
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1068 - 1075
  • [47] Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study
    Mancuso, Maria Elisa
    Mahlangu, Johnny
    Sidonio, Robert, Jr.
    Trask, Peter
    Uguen, Marianne
    Chang, Tiffany
    Shima, Midori
    Young, Guy
    Oldenburg, Johannes
    von Mackensen, Sylvia
    HAEMOPHILIA, 2020, 26 (06) : 1009 - 1018
  • [48] Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea
    Lee, Hankil
    Cho, Hyeonseok
    Han, Jung Woo
    Kim, Ah-Young
    Park, Seonyoung
    Lee, Minjun
    Cho, Sunghwa
    Baik, Deborah
    Kang, Hye-Young
    HAEMOPHILIA, 2021, 27 (01) : E12 - E21
  • [49] Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study
    Feldman, BM
    Pai, M
    Rivard, GE
    Israels, S
    Poon, MC
    Demers, C
    Robinson, S
    Luke, KH
    Wu, JKM
    Gill, K
    Lillicrap, D
    Babyn, P
    McLimont, M
    Blanchette, VS
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (06) : 1228 - 1236
  • [50] Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis
    Raventos, Aida
    Arias-Salgado, Elena G.
    Perez, Alba
    Alvarez-Roman, Maria Teresa
    Butta, Nora V.
    Monzon Manzano, Elena
    Acuna, Paula
    Jimenez-Yuste, Victor
    Costa, Montserrat
    Bravo, Maria Isabel
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 25 (01)
12345